Regulatory milestone for lorundrostat
Mineralys Therapeutics (MLYS) recently reported that the FDA accepted its New Drug Application for lorundrostat in hypertension, while also updating investors on the Explore OSA trial in obstructive sleep apnea.
See our latest analysis for Mineralys Therapeutics.
Mineralys Therapeutics’ share price has pulled back over the past quarter, with a 90 day share price return of 19.92% decline and year to date return of 20.72% decline. However, the 1 year total shareholder return of about 2.4x indicates that longer term momentum has still been strong.
If this kind of regulatory driven story has your attention, it could be a good moment to widen your watchlist and check out 37 healthcare AI stocks
With the stock down over the past quarter but still up strongly over 1 year, and trading below analyst targets, the key question is simple: is Mineralys still undervalued or is the market already pricing in future growth?
Most Popular Narrative: 44.4% Undervalued
Mineralys last closed at $28.31, while the most followed narrative pegs fair value at $50.88, creating a wide gap that hinges on lorundrostat’s commercialization path.
Progress toward an NDA filing for lorundrostat in uncontrolled and resistant hypertension, supported by multiple Phase III and proof of concept trials, positions the company to potentially transition from a pure R&D story toward a revenue generating profile, which could materially affect future revenue and earnings visibility.
Want to see what sits behind that valuation gap? The narrative leans on ambitious revenue ramp up, margin lift and a punchy future earnings multiple. The exact mix of those ingredients might surprise you.
Result: Fair Value of $50.88 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this hinges on lorundrostat clearing regulatory hurdles and standing out against rival aldosterone synthase inhibitors, where setbacks could quickly challenge that undervalued narrative.
Find out about the key risks to this Mineralys Therapeutics narrative.
Another angle on valuation
That undervalued story comes from an analyst driven narrative. Looking at price based metrics, Mineralys trades on a P/B of 3.6x compared with 2.2x for the wider US Biotechs group and 10.9x for peers, which points to a higher bar for execution. Which signal do you trust more?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With a mixed picture of risks and rewards, do you want to rely on headlines or your own judgment? Act while the data is fresh and weigh up the 1 key reward and 3 important warning signs
Looking for more investment ideas?
If Mineralys is already on your radar, do not stop there. Broaden your watchlist now so you are not the one hearing about the next opportunity after it moves.
- Hunt for value by scanning companies that combine quality fundamentals with attractive pricing through 61 high quality undervalued stocks.
- Prioritize resilience and sleep easier at night by focusing on 70 resilient stocks with low risk scores that aim to keep big setbacks in check.
- Get ahead of the crowd by checking a screener containing 25 high quality undiscovered gems before they hit the mainstream conversation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com